Profund Advisors LLC Cuts Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Profund Advisors LLC lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 27.1% in the second quarter, Holdings Channel reports. The fund owned 86,935 shares of the biopharmaceutical company’s stock after selling 32,323 shares during the period. Profund Advisors LLC’s holdings in Amicus Therapeutics were worth $862,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sei Investments Co. raised its holdings in shares of Amicus Therapeutics by 8.7% in the 2nd quarter. Sei Investments Co. now owns 242,131 shares of the biopharmaceutical company’s stock valued at $2,403,000 after purchasing an additional 19,416 shares in the last quarter. Inspire Investing LLC increased its holdings in Amicus Therapeutics by 13.3% in the second quarter. Inspire Investing LLC now owns 35,242 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 4,148 shares during the last quarter. Blair William & Co. IL raised its stake in Amicus Therapeutics by 15.2% in the second quarter. Blair William & Co. IL now owns 47,254 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 6,237 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in Amicus Therapeutics by 24.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after buying an additional 48,802 shares during the last quarter. Finally, Old West Investment Management LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $471,000.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,100 shares of company stock valued at $226,375. Company insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $11.22 on Wednesday. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The company has a market capitalization of $3.32 billion, a P/E ratio of -22.90 and a beta of 0.69. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The company’s fifty day moving average is $11.06 and its two-hundred day moving average is $10.69.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business’s revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.15) earnings per share. Analysts forecast that Amicus Therapeutics, Inc. will post -0.08 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.